JAK Inhibitors in the Evolving Treatment Landscape of Atopic Dermatitis

Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).

Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.

Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.

Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.

Alexandra Golant, MD, comments on the boxed warnings on all currently approved JAK inhibitors, as well as the commonly used treatments in dermatology that have boxed warnings.

Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.

Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.

Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.

Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.

Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.